Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects
about
Profile of brivaracetam and its potential in the treatment of epilepsyBrivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence baseThe pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men[Brivaracetam for add-on treatment in focal epilepsy].Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Drug interactions involving the new second- and third-generation antiepileptic drugs.New developments in the management of partial-onset epilepsy: role of brivaracetam.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Brivaracetam for the treatment of epilepsy.Methodologies used to identify and characterize interactions among antiepileptic drugs.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Evaluation of brivaracetam: a new drug to treat epilepsy.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.Brivaracetam disposition in mild to severe hepatic impairment.Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.Effect of brivaracetam on CYP3A activity, measured by oral midazolam.Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy.Brivaracetam: a novel antiepileptic drug for focal-onset seizures.A review of the pharmacology and clinical efficacy of brivaracetam.Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.Assessing Confidence in Predictions Using Veracity and Utility - A Case Study on the Prediction of Mammalian Metabolism by Meteor Nexus.Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus.Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women.
P2860
Q26776317-1530D57D-C274-48C7-ACAA-E640DADCE584Q28076065-B22476CD-4D52-4582-942C-F0E77122E66AQ28272717-EDC0CE37-3F4A-46F2-9C7A-310568B8ADE0Q30390285-EF8B0C43-4C61-4E02-8DD0-ADE1338AECF3Q30662550-EAD85B7A-ED24-4ED5-BB11-49BA6E4DD800Q35761335-B37CDBF5-85CF-449A-9FD0-34CE7AD00A7DQ37658910-D61F7010-EC86-47F5-B282-29DBC3DD59B3Q37693757-9F1710F2-8F6A-4151-BFC9-DA6BF1CCFE42Q37754477-EB003E34-340E-42C4-979A-D894169CFD79Q37831297-EA52B246-4F73-4DC1-914A-A6C572EB07DDQ37891095-D164F12B-9150-4F2A-86E9-FBCAC2223716Q38018676-54FA8601-2EE2-49C1-B535-BD773B4BFFBFQ38614499-C77537D4-49A3-4ABC-B42B-09A667A8667AQ38626838-A37D11EA-189E-4CB4-BDC7-5779EB542143Q38652806-60E14D4C-A4CD-4FDF-B2E0-E61F59C32140Q38694479-8CF8EC8E-0019-4C9F-98D8-DE7360178486Q38739649-4F1C9EF2-C18B-42B3-9D41-3CA69DA12D61Q38752407-21FB5334-2F29-4655-B0FF-126545729495Q38844513-0B467736-E4F5-4796-ADD5-505FDDB749A8Q38915714-4CAB8242-F862-49CC-8DFD-9DF833A77966Q38922348-C1467EB6-7CB3-48D9-A861-C52908AD54B1Q38985697-EE9D675D-330E-43B5-B7AB-962C54132127Q39794501-DD538FE3-ED46-486D-B97A-EF80448C90A8Q39899497-1E4DC9C7-782E-4820-9BB2-C2FDA6C76F43Q40215881-075ABC04-0FF4-4B9D-BC1E-DA4B9A4E76D2Q44231616-84A46280-9A39-4602-A53E-CA99AABB02B0Q44773924-9A68DE77-37E2-4DBF-A9AA-1998F53F0246Q47774665-AC04136B-E0BF-4D84-BEFD-102FEDD2407FQ47853821-957C18EF-894D-441A-9EA6-22F01F593D74Q49253776-29083E41-42E4-4997-BD81-8D17901E62D3Q49700507-2E763592-FB69-4CED-BF20-D9759B7EE405Q51771465-38F24D9C-79E5-45D3-AA20-CD990E4CF62DQ52837113-96B7149F-036C-4562-A042-228B85EBBEE4Q53073031-0736F72B-5734-42A3-B847-D476255CB63FQ54375873-439DC46D-1827-405A-AAB5-544B103A121C
P2860
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@ast
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@en
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@nl
type
label
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@ast
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@en
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@nl
prefLabel
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@ast
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@en
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@nl
P2093
P356
P1476
Pharmacokinetics and metabolis ...... 2A ligand, in healthy subjects
@en
P2093
Alain Coquette
Armel Stockis
Maria Laura Sargentini-Maier
Pascal Espié
P356
10.1124/DMD.107.017129
P407
P577
2008-01-01T00:00:00Z